Crescent Capital Operating Margin vs. Net Income

CCAP Stock  USD 14.85  0.11  0.75%   
Taking into consideration Crescent Capital's profitability measurements, Crescent Capital BDC is yielding more profit at this time then in previous quarter. It has a moderate probability of reporting better profitability numbers in February. Profitability indicators assess Crescent Capital's ability to earn profits and add value for shareholders.

Crescent Capital Operating Profit Margin

0.5

As of 01/16/2026, Operating Cash Flow Sales Ratio is likely to grow to 0.55, while Price To Sales Ratio is likely to drop 5.46. At this time, Crescent Capital's Interest Income is relatively stable compared to the past year. As of 01/16/2026, Operating Income is likely to grow to about 90.2 M, while Net Interest Income is likely to drop slightly above 71.5 M. As of 01/16/2026, Gross Profit is likely to grow to about 100.8 M. Also, Pretax Profit Margin is likely to grow to 0.50
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.740.67
Significantly Up
Slightly volatile
For Crescent Capital profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Crescent Capital to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Crescent Capital BDC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Crescent Capital's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Crescent Capital BDC over time as well as its relative position and ranking within its peers.
Check out Trending Equities.
The next projected EPS of Crescent Capital is estimated to be 0.39875 with future projections ranging from a low of 0.375 to a high of 0.4125. Crescent Capital's most recent 12-month trailing earnings per share (EPS TTM) is at 0.97. Please be aware that the consensus of earnings estimates for Crescent Capital BDC is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Crescent Capital is projected to generate 0.39875 in earnings per share on the 31st of December 2026. Crescent Capital earnings estimates show analyst consensus about projected Crescent Capital BDC EPS (Earning Per Share). It derives the highest and the lowest estimates based on Crescent Capital's historical volatility. Many public companies, such as Crescent Capital, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Crescent Capital's earnings estimates, investors can diagnose different trends across Crescent Capital's analyst sentiment over time as well as compare current estimates against different timeframes.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crescent Capital. If investors know Crescent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crescent Capital listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.54)
Dividend Share
1.68
Earnings Share
0.97
Revenue Per Share
4.665
Quarterly Revenue Growth
(0.20)
The market value of Crescent Capital BDC is measured differently than its book value, which is the value of Crescent that is recorded on the company's balance sheet. Investors also form their own opinion of Crescent Capital's value that differs from its market value or its book value, called intrinsic value, which is Crescent Capital's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crescent Capital's market value can be influenced by many factors that don't directly affect Crescent Capital's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crescent Capital's value and its price as these two are different measures arrived at by different means. Investors typically determine if Crescent Capital is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crescent Capital's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Crescent Capital BDC Net Income vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Crescent Capital's current stock value. Our valuation model uses many indicators to compare Crescent Capital value to that of its competitors to determine the firm's financial worth.
Crescent Capital BDC is rated fourth in operating margin category among its peers. It is rated second in net income category among its peers making up about  97,976,586  of Net Income per Operating Margin. At this time, Crescent Capital's Operating Profit Margin is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Crescent Capital by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Crescent Net Income vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Crescent Capital

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.75 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Crescent Capital

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
73.65 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Crescent Net Income Comparison

Crescent Capital is currently under evaluation in net income category among its peers.

Crescent Capital Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Crescent Capital, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Crescent Capital will eventually generate negative long term returns. The profitability progress is the general direction of Crescent Capital's change in net profit over the period of time. It can combine multiple indicators of Crescent Capital, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Interest Income210.4 M220.9 M
Operating Income86 M90.2 M
Net Income From Continuing Ops84.7 M88.9 M
Income Before Tax86 M90.2 M
Total Other Income Expense Net-57.5 M-54.7 M
Net Income Applicable To Common Shares17.9 M28.9 M
Net Income84.7 M88.9 M
Income Tax Expense1.3 M826.9 K
Net Interest Income142.6 M71.5 M
Non Operating Income Net Other-39 M-41 M
Change To Netincome68.7 M72.1 M
Net Income Per Share 1.79  0.98 
Income Quality 1.29  1.23 
Net Income Per E B T 1.13  1.08 

Crescent Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Crescent Capital. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Crescent Capital position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Crescent Capital's important profitability drivers and their relationship over time.

Crescent Capital Earnings Estimation Breakdown

The calculation of Crescent Capital's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Crescent Capital is estimated to be 0.39875 with the future projection ranging from a low of 0.375 to a high of 0.4125. Please be aware that this consensus of annual earnings estimates for Crescent Capital BDC is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
0.0
0.38
Lowest
Expected EPS
0.39875
0.41
Highest

Crescent Capital Earnings Projection Consensus

Suppose the current estimates of Crescent Capital's value are higher than the current market price of the Crescent Capital stock. In this case, investors may conclude that Crescent Capital is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Crescent Capital's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2026Current EPS (TTM)
676.95%
0.0
0.39875
0.97

Crescent Capital Earnings per Share Projection vs Actual

Actual Earning per Share of Crescent Capital refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Crescent Capital BDC predict the company's earnings will be in the future. The higher the earnings per share of Crescent Capital, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Crescent Capital Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Crescent Capital, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Crescent Capital should always be considered in relation to other companies to make a more educated investment decision.

Crescent Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Crescent Capital's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
null
nullnullnullnull
null
nullnullnullnull
2025-11-14
2025-09-300.470.46-0.01
2025-08-13
2025-06-300.470.41-0.0612 
2025-05-14
2025-03-310.530.45-0.0815 
2025-02-19
2024-12-310.560.54-0.02
2024-11-06
2024-09-300.5750.412-0.16328 
2024-08-12
2024-06-300.580.590.01
2024-05-08
2024-03-310.60.630.03
2024-02-21
2023-12-310.570.610.04
2023-11-08
2023-09-300.560.590.03
2023-08-09
2023-06-300.550.560.01
2023-05-10
2023-03-310.480.540.0612 
2023-02-22
2022-12-310.440.490.0511 
2022-11-09
2022-09-300.440.42-0.02
2022-08-10
2022-06-300.410.410.0
2022-05-09
2022-03-310.410.420.01
2022-02-23
2021-12-310.420.430.01
2021-11-10
2021-09-300.410.480.0717 
2021-08-11
2021-06-300.460.530.0715 
2021-05-12
2021-03-310.470.46-0.01
2021-02-24
2020-12-310.460.470.01
2020-11-04
2020-09-300.480.43-0.0510 
2020-08-10
2020-06-300.430.460.03
2020-05-12
2020-03-310.40.440.0410 
2020-03-04
2019-12-310.480.45-0.03
2019-11-07
2019-09-300.490.490.0
2019-08-13
2019-06-3000.410.41
2019-05-10
2019-03-3100.420.42

Use Crescent Capital in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crescent Capital position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crescent Capital will appreciate offsetting losses from the drop in the long position's value.

Crescent Capital Pair Trading

Crescent Capital BDC Pair Trading Analysis

The ability to find closely correlated positions to Crescent Capital could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crescent Capital when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crescent Capital - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crescent Capital BDC to buy it.
The correlation of Crescent Capital is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crescent Capital moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crescent Capital BDC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crescent Capital can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Crescent Capital position

In addition to having Crescent Capital in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cancer Fighters Thematic Idea Now

Cancer Fighters
Cancer Fighters Theme
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Crescent Stock Analysis

When running Crescent Capital's price analysis, check to measure Crescent Capital's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crescent Capital is operating at the current time. Most of Crescent Capital's value examination focuses on studying past and present price action to predict the probability of Crescent Capital's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crescent Capital's price. Additionally, you may evaluate how the addition of Crescent Capital to your portfolios can decrease your overall portfolio volatility.